Original Article

You have full text access to this OnlineOpen article

Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma†

  1. Laura L. Kruper MD, MSCE1,2,‡,*,
  2. Francis R. Spitz MD1,2,
  3. Brian J. Czerniecki MD, PHD1,2,
  4. Douglas L. Fraker MD1,2,
  5. Anne Blackwood-Chirchir MD, MSCE1,3,
  6. Michael E. Ming MD, MSCE1,4,
  7. David E. Elder MB, CHB1,5,
  8. Rosalie Elenitsas MD1,4,
  9. DuPont Guerry MD1,6,
  10. Phyllis A. Gimotty PhD1,3

Article first published online: 20 OCT 2006

DOI: 10.1002/cncr.22295

Issue

Cancer

Cancer

Volume 107, Issue 10, pages 2436–2445, 15 November 2006

Additional Information

How to Cite

Kruper, L. L., Spitz, F. R., Czerniecki, B. J., Fraker, D. L., Blackwood-Chirchir, A., Ming, M. E., Elder, D. E., Elenitsas, R., Guerry, D. and Gimotty, P. A. (2006), Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer, 107: 2436–2445. doi: 10.1002/cncr.22295

Author Information

  1. 1

    Melanoma Program of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania

  2. 2

    Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

  3. 3

    Department of Biostatistics and Epidemiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

  4. 4

    Department of Dermatopathology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

  5. 5

    Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

  6. 6

    Department of Medicine, Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

  1. ‡

    Fax: (215) 573-4865

*Department of Surgery, Hospital of the University of Pennsylvania, 4th Floor Maloney Building, 3400 Spruce St., Philadelphia, PA 19104

  1. †

    Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13–17, 2005.

  2. ‡

    Fax: (215) 573-4865

Publication History

  1. Issue published online: 8 NOV 2006
  2. Article first published online: 20 OCT 2006
  3. Manuscript Accepted: 7 SEP 2006
  4. Manuscript Revised: 1 SEP 2006
  5. Manuscript Received: 24 FEB 2006

Funded by

  • SPORE on Skin Cancer. Grant Number: CA-093372
  • NRSA Cancer Epidemiology Training. Grant Number: T32 CA-009679

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (431K)

REFERENCES

  • 1
    Balch C, Buzaid A, Soong S, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635–3648.
  • 2
    Morton D, Wen D, Foshag L, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992; 127: 392–399.
  • 3
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. NEJM. 2006; 355: 1307–1317.
  • 4
    National Comprehensive Cancer Network: melanoma: clinical practice guidelines in oncology. v. 1. 2005. Available at http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf
  • 5
    Gershenwald J, Thompson W, Mansfield P, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999; 17: 976–983.
  • 6
    McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement [Commentary]. J Clin Oncol. 2001; 19: 2851–2855.
  • 7
    McMasters K, Wong S, Edwards MJ, et al. Factors that predict the presence of sentinel node metastasis in patients with melanoma. Surgery. 2001; 130: 151–156.
  • 8
    Mraz-Gernhard S, Sagebiel RW, Kashani-Sabet M, et al. Prediction of sentinel node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch Dermatol. 1998; 134: 983–987.
  • 9
    Landi G, Polverelli M, Moscatelli G, et al. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J Eur Acad Dermatol Venereol. 2000; 14: 35–45.
    Direct Link:
  • 10
    Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000; 7: 469–474.
  • 11
    Nguyen CL, McClay EF, Cole DJ, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg. 2001; 181: 8–11.
  • 12
    Rousseau DLJr., Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003; 10: 569–574.
  • 13
    Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000; 89: 453–462.
    Direct Link:
  • 14
    Sondak VD, Taylor MG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004; 11: 247–258.
  • 15
    Berk DR, Johnson DL, Uzieblo A, et al. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997–2004. Arch Dermatol. 2005; 141: 1016–1022.
  • 16
    Morton DL, Hoon DSB, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Ann Surg. 2003; 238: 538–550.
  • 17
    Roka F, Kittler H, Cauzig P, et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer. 2005; 92: 662–667.
  • 18
    Porter GA, Ross MI, Berman RS, et al. Significance of multiple modal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000; 7: 256–261.
  • 19
    Bedrosian I, Faries M, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1mm) with vertical growth phase. Ann Surg Oncol. 2000; 7: 262–267.
  • 20
    Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg. 2003; 112: 486–497.
  • 21
    Clark WH, Elder DE, Guerry D, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81: 1893–1904.
  • 22
    Elder DE, Guerry D, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol. 1984; 6: 55S–61S.
  • 23
    Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005; 18: 368–384.
    Direct Link:
  • 24
    Guerry D, Synnestvedt M, Elder DE, et al. Lessons learned from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol. 1993; 100: 342S–345S.
  • 25
    Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005; 12: 449–458.
  • 26
    Balch CM, Riley LB, Bae YJ, et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg. 1990; 125: 200–205.
  • 27
    Clemente CG, Mihm MC, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77: 1303–1310.
    Direct Link:
  • 28
    Mihm MCJr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996; 74: 43–47.
  • 29
    Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163: 1765–1770.
  • 30
    Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma. Am J Clin Pathol. 2002; 118: 504–511.
  • 31
    McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001; 8: 192–197.
  • 32
    Hosmer DW, Lemeshow SL. Applied logistic regression, 2nd ed. New York: John Wiley & Sons, 2000.
  • 33
    Stata statistical software: release 8.0. College Station, TX: STATA, 2003.
  • 34
    Steinberg D, Colla P. CART: Tree-structured non-parametric data analysis. San Diego: Salford Systems, 1995.
  • 35
    Breiman L, Friedman JH, Olshen RA, et al. Classification and regression trees. Boca Raton, FL: Chapman and Hall, 1984.
  • 36
    Gimotty PA, VanBelle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005; 23: 8048–8056.
  • 37
    Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metasasis in melanoma with better discrimination than the American Joint Committee on Cancer Staging System. Ann Surg Oncol. 2005; 282–288.
  • 38
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Public-Use Data (1973–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
  • 39
    Bleicher R, Essner R, Foshag L, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003; 21: 1326–1331.
  • 40
    Jacobs I, Chang C, DasGupta T. Role of sentinel lymph node biopsy in patients with thin (≤1mm) primary melanoma. Ann Surg Oncol. 2003; 10: 558–556.
  • 41
    Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004; 22: 3668–3676.
  • 42
    Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence based on histopathologic features. Dermatol Ther. 2005; 18: 369–385.
    Direct Link:
View Full Article (HTML) Get PDF (431K)